NovoCure (NVCR) Capital Expenditures Growth (5y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.29% |
| Dec 31, 2025 | -3.19% |
| Sep 30, 2025 | 15.24% |
| Jun 30, 2025 | 10.60% |
| Mar 31, 2025 | 27.80% |
| Dec 31, 2024 | 23.96% |
| Sep 30, 2024 | 31.59% |
| Jun 30, 2024 | 36.71% |
| Mar 31, 2024 | 38.35% |
| Dec 31, 2023 | 30.63% |
| Sep 30, 2023 | 39.91% |
| Jun 30, 2023 | 52.01% |
| Mar 31, 2023 | 52.55% |
| Dec 31, 2022 | 3.50% |
| Sep 30, 2022 | 59.99% |
| Jun 30, 2022 | 61.50% |
| Mar 31, 2022 | 37.64% |
| Dec 31, 2021 | 87.37% |
| Sep 30, 2021 | 13.96% |
| Jun 30, 2021 | 2.29% |
| Mar 31, 2021 | 31.77% |
| Dec 31, 2020 | 40.44% |
| Sep 30, 2020 | 18.39% |
| Jun 30, 2020 | 12.89% |
| Mar 31, 2020 | 38.57% |
| Dec 31, 2019 | 49.73% |